The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluvastatin formulations

[1]  J. Tardif,et al.  Pharmacogenetics of Lipid-Lowering Agents: an Update Review on Genotype-Dependent Effects of HDL-Targetingand Statin Therapies , 2017, Current Atherosclerosis Reports.

[2]  Limi Elizabeth Mathew,et al.  Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  H. Völzke,et al.  Function-impairing polymorphisms of the hepatic uptake transporter SLCO1B1 modify the therapeutic efficacy of statins in a population-based cohort , 2015, Pharmacogenetics and genomics.

[4]  L Gong,et al.  The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update , 2014, Clinical pharmacology and therapeutics.

[5]  N. Mirošević Skvrce,et al.  CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. , 2013, Pharmacogenomics.

[6]  S. Zeng,et al.  CYP2C9*3(1075A>C), MDR1 G2677T/A and MDR1 C3435T are Determinants of Inter-subject Variability in Fluvastatin Pharmacokinetics in Healthy Chinese Volunteers , 2012, Arzneimittelforschung/Drug Research.

[7]  O. Slanař,et al.  Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[8]  J. R. Zhu,et al.  The Difference in Pharmacokinetics and Pharmacodynamics between Extended-Release Fluvastatin and Immediate-Release Fluvastatin in Healthy Chinese Subjects , 2012, Journal of biomedicine & biotechnology.

[9]  P. Neuvonen,et al.  Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate , 2008, Pharmacogenetics and genomics.

[10]  P. Giral,et al.  Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. , 2008, Pharmacogenomics.

[11]  C. Funk,et al.  Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3 , 2007, Drug Metabolism and Disposition.

[12]  M. Banach,et al.  Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention , 2006, Journal of cardiovascular pharmacology.

[13]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[14]  D. Keppler,et al.  Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells , 2005, Molecular Pharmacology.

[15]  M. Hubert,et al.  Steady‐state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol® XL , 2004, Biopharmaceutics & drug disposition.

[16]  Christian Meisel,et al.  Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol‐lowering activity of (−)‐3s,5r‐fluvastatin and (+)‐3r,5s‐fluvastatin in healthy volunteers , 2003, Clinical pharmacology and therapeutics.

[17]  J. Lasalle,et al.  Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. , 2003, Clinical therapeutics.

[18]  M. Yasuhara,et al.  Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. , 1999, Biochemical pharmacology.

[19]  J. Banga,et al.  Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group. , 1994, British journal of clinical pharmacology.

[20]  P. Neuvonen,et al.  Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin , 2008, Clinical pharmacokinetics.

[21]  J. Paulauskis,et al.  An association study of 43 SNPs in 16 candidate genes with atorvastatin response , 2005, The Pharmacogenomics Journal.

[22]  C. Luley,et al.  Comparison of the efficacy and tolerability of fluvastatin extended-release and immediate-release formulations in the treatment of primary hypercholesterolemia: a randomized trial. , 2001, Clinical therapeutics.